Diabetes Flashcards

1
Q

Pancreatic islet innervation

A

PSNS: vagus, ACh mediated –> increase insulin release
SNS: Post-ganglionic fibers originating in celiac ganglion (foregut)
- NE mediated –> inhibit insulin secretion
- E from adrenal gland –> neurohormonal action to decrease insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type 1 DM pathophys

A

Genetic + immune + environmental factors –> cell destruction
Strong genetic correlation with certain HLA loci, associated with other autoimmune diseases
- HLA-DR, HLA-DQ alleles
-Polygenic
- 50% concordance in identical twins
Viruses: coxsackie, mumps, rubella
Lymphocyte infiltration –> islet cell destruction
- islet cell Ab present in up to 60-85% of cases (best predictor of disease)
- up to 69% have Ab against insulin

Possibilities:

  • molecular mimicry
  • bystandar activation - nonspecific infection causes cytokine release into pancreas
  • beta cell apoptosis

80% beta cell destruction –> symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Type 2 DM pathophys

A

Impaired insulin secretion AND peripheral insulin resistance
>90% concordance in identical twins - strong genetic component
1) Glucose tolerance normal, insulin resistance high - compensation by increased insulni secretion
2) Beta cells unable to maintain hyperinsulinemic state –> glucose intolerance, diabetes

Associated with obesity, particularly intraabdominal obesity
Resistance involves genetic and/or acquired post-receptor defects in insulin action

Rare (5%) , single gene mutation = “mature onset diabetes of the young”
genes that regultae beta cell mass or function - MODY2, glucokinase, impaired insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Causes of progressive loss of insulin secretion in type 2 diabetes

A

glucose toxicity and lipotoxicity to beta cells
beta cell exhaustion/stress
pro-inflammatory cytokines: beta cells during hyperglycemic stress make pro-inflammatory cytokines
Islet myloid deposits: toxic amyloid deposits composed of islet amyloid polypeptide (IAPP) found in most T2D patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nesidioblastosis

A

= hyperinsulinemic hypoglycemia
excessive function of pancreatic beta cells with abnormal microscopic appearance
aka congenital hyperinsulinism
islet cell enlargement, islet cell dysplasia, beta cell hyperplasia/budding from ductal epithelium
Proliferation of islet cells from pancreatic ducts –> hypoglycemia and hyperinsulinemia in infants and newborns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Insulinoma

A

Tumour of the pancreas
Symptoms of hypoglycemia - improved by eating
tx surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 1 DM onset and epidemiology

A

<30 yrs old, acute
Caucasians
Rare in blacks, hispanics, asians
5-10% of DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Type 2 DM onset and epidemiology

A

Usually >40, gradual
Black, hispanics, Asians, aboriginals
>90% of DM
5% of population, and increasing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Syndrome X

A

etiology of type 2 DM

central obesity, hyperlipidemia, hyperinsulinemia, HTN, diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Type 1 DM clinical features

A

normal to wasted body
polydipsia
polyuria
hyperphagia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Type 2 DM clinical features

A
overweight with central obesity
HONDA patient
don't usually get ketosis
often normal insulin levels
acanthosis nigricans (dark pigmentation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acute complications of DM

A
Diabetic ketoacidosis (Type 1)
Hyperglycemic hyperosmolar state (type 2, elderly)
Hypoglycemia
Myocardial infarction
Stroke
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diabetic ketoacidosis pathophys

A

Hyperglycemia leading to:

  • osmotic diuresis - loss of electrolytes
  • ileus from electrolyte abnormalities - voimting
  • polyuria, polydipsia, dehydration, hypotension, tachycardia and peripheral circulatory failure
  • decrease intravascular volume –> aldosterone secretion via RAAS –> potassium loss

Upregulation of glucagon

  • increased lipolysis and ketogenesis –> accumulation (beta-hydroxybutyrate)
  • metabolic acidosis + compensatory hyperventilation
  • acidosis –> K out of cells, then lost into urine

+ insulin treatment –> activates Na/K pump, K sequestered into cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperglycemic hyperosmolar state pathphys

A

Residual activity in patients –> lipolysis not activated, no ketoacidosis
Ppt factor = increased insulin resistance triggered by illness/drugs
Major problem = extreme dehydration secondary to osmotic diuresis
- glucose level >45
- contraction of blood volume - can become hypoxic - lactic acidosis may develop due to anaerobism
- sodium concentrations may become elevated secondary to diuresis
- confusion and lethargy as serum osmolality >300; coma >340

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic complications of DM (categories)

A
vascular
renal
eye
neurologic
skin
infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronic complications of DM - pathogenesis

A

Non-enzymatic glycosylation of proteins. 3 stages:
1) Schiff base formation (reversible)
2) Amadori product formation (reversible)
3) advanced glycosylation end product formation (AGEs) - irreversible
Pathology due to accumulation of AGEs in vessel walls

Intracellular hyperglycemia
- glucose accumulates in tissues that do not require insulin for entry: nerves, lens, kidneys, blood vessels
Metabolized to sorbitol and fructose –> osmotic load –> injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DM vascular disease

A

Diabetic microangiopathy: diffuse tihckening of basement membrane, microaneurysm formation

Hyaline arteriolosclerosis: thickening of vessel walls –> HTN

Accelerated atherosclerosis: coronary arter, cerebrovascular, peripheral vascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

DM renal disease

A

DM most common cause of end-stage renal disease in north america
Glomerulosclerosis
Renal vascular lesion
Infections - acute/chronic pyelonephritis more common/severe in DM
Papillary necrosis - ischemic (type 1); sloughed papilla may cause obstruction
Autonomic neuropathy - urinary retention in bladder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Glomerulosclerosis (DM)

A

Microalbuminuria - earliest clinically detectable feature
Diffuse glomerulosclerosis:
- diffuse increase in the mesangial matrix in glomerulus
-not specific

Nodular glomerulosclerosis (Kimmelstiel-Wilson lesion)

  • distinctive ball-like deposits of matrix in mesangial core of clomerulus
  • tends to occur at periphery of glomerulus pushing capillaries aside
  • presence of nodular glomerulosclerosis = DM
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Renal vascular lesions (DM)

A

renal atherosclerosis - both large and small vessels

Renal arteriolosclerosis - afferent and efferent arteriole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Eye disease (DM)

A

diabetic retinopathy
cataracts - usually premature development of senile nuclear sclerosis and cortical cataract, not hyperglycemic cataract due to sorbitol (rare)
glaucoma - neovascularization may affect iris (rare); block drainage of aqueous fluid
ocular palsies- usually secondary to CNIII infarct; Argyll Robertson pupils and Horner’s syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Diabetic retinopathy classifications

A

Background (non-proliferative)
Pre-proliferative (advanced non-proliferative)
Proliferative retinopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Background diabetic retinopathy

A

Increased vascular permeability and retinal ischemia (microangiopathy)
earliest features = microaneurysms (dots)
Intra-retinal hemorrhages (blots)
hemorrhage into nerve fibre layer (flame shape)
hard exudates (lipid deposits)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Pre-proliferative diabetic retinopathy

A

increased caliber and beading of retinal veins
cotton wool spots - microinfarcts of nerve fibre layer with fuzzy edges
arteriolar hyalinization (cytoid bodies)
large areas of capillary non-perfusion in absence of new vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Proliferative retinopathy

A

Ischemia and hypoxia of retina –> neovascularization
fragile new vessels rupture and bleed
fibrosis, then contraction causing increased traction on retina
possible retinal detachment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

DM neurologic disease

A

distal symmetric sensori-motor polyneuropathy
Autonomic neuropathy
diabetic polyradiculopathy (diabetic amyotrophy)
mononeuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Distal symmetric sensori-motor polyneuropathy

A

Most common neuropathy in diabetics, unknown etiology
Sensori-motor nerves affected (motor effects usually less pronounced)
decreased sensation in distal extremities
All sensory modalities affected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Autonomic neuropathy - DM

A

ED

bowel dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Diabetic polyradiculopathy

A

uncommon, usually males with type 2
axon loss at level of nerve root (L2-L4, maybe L5)
rapid development of pain, weakness of upper legs (esp. anterior thighs)

30
Q

Mononeuropathy

A

single/mnultiple, peripheral or cranial nerves (compression/entrapment or infarction)
asymmetric

31
Q

DM skin disease

A

necrobiosis lipoidica diabeticorum (non-scaling plaque on shi nwith yellow skin, telangiectasia)
granuloma annulare (lesion with raised annular border on dorsum of hand/arm)
injection site lipodystrophy
recurrent infections (esp Candida)
ulcers

32
Q

DM - infection

A

malignant otitis externa (Pseudomonas)
rhinocerebral mucormycosis (increased risk if ketoacidotic)
emphysematous cholecystitis
emphysematous pyelonephritis/papillary necrosis
mucocutaneous candidal infections
soft tissue infection - diabetic foot

33
Q

DM prevention/screening/diagnosis

A

Inial: fasting plasma glucose (<6.1)
oGTT - higher sensitivity
HbA1C (4-6%)

34
Q

Insulin PK

A

based on diffusion time

35
Q

Oral hypoglycemic agents

A
sulfonylureas
meglitinides
alpha-glucosidase inhibitors
biguanides
thiaxolindinediones
incretin
36
Q

Sulfonylurea MOA

A

Bind to SU receptors on beta cells
closure of K-ATP channels –> depolarization of cell –> CaV channels open –> Ca influx –> insulin release

Glucose-independent insulin release

37
Q

Sulfonylurea PK

A

metabolized in liver

mostly excreted by the kidney

38
Q

Sulfonylurea effects

A

improve hyperglycemia and glucotoxicity

reduces HbA1c by 1-2%

39
Q

Sulfonylurea SEs

A

weight gain

hypoglycemia (esp in RF, liver failure and elderly)

40
Q

SU prototype

A

-ide

41
Q

Meglitinides MOA

A

insulin secretagogues
Bind to K-ATP channels on beta cells
Glucose-dependent insulin release

42
Q

Meglitinide PKs

A

short-acting, take after meals
liver metabolism
90% fecal excretion

43
Q

meglitinide suffix

A

-glinide

44
Q

meglitinide effects

A

attenuate post-prandial hyperglycemia

reduces HbA1c by 1-2%

45
Q

Alpha-glucosidase inhibitor suffix

A

-acarbose

46
Q

Alpha-glucosidase inhibitor MOA

A

decreased conversion of complex CHO to monosaccharides

47
Q

Alpha-glucosidase inhibitor PK

A

excreted in feces/urine

take with meals

48
Q

Alpha-glucosidase inhibitor effect

A

reduce HbA1c by 0.4-1%

49
Q

Alpha-glucosidase inhibitor SE

A

weight neutral
GI symptoms
hypoglycemia

50
Q

Biguanide prototype

A

metformin

51
Q

Biguanide MOA

A

reduce hepatic gluconeogenesis
increase insulin-stimulated glucose transport at muscle
decrease FA oxidation

52
Q

Biguanide PK

A

onset within 1-2 hour
not metabolized
eliminated via urine

53
Q

Biguanide effects

A

reduce HbA1c by 1-2%
reduces triglycerides and LDL cholesterol
increases HDL
reduction in MI

54
Q

metformin SE

A
wt loss
less hyperglycemia
GI
metallic taste
lactic acidosis (rare)
55
Q

Thiaxolindinedione suffix

A

-glitazone

56
Q

Thiaxolindinedione MOA

A

enhance responsiveness and efficiency of beta cells

57
Q

Thiaxolindinedione PK

A

durable monotherapy

requires 6-12 weeks for maximal effect

58
Q

Thiaxolindinedione effects

A

Lowers HbA1c by 1-2% over 6-12 weeks
may increase HDL and LDL, reduce TAGs
may improve CV effects

59
Q

Thiaxolindinedione SEs

A

weight gain
fluid retention (contraindicated in CHF)
rare risk of macular edema and fractures
hepatotoxicity with troglitazone (less wiht newer agents)

60
Q

GLP1 agonist suffix

A

-tide

61
Q

GLP1 agonist MOA

A
incretin
Actions of endogeneous GLP1:
-stimulates insulin secretion
- suppresses glucagon secretion
-slows gastric emptying
-improves insulin sensitivity
-reduces food intake
62
Q

GLP1 agonist PK

A

injected

63
Q

GLP1 agonist effect

A

lowers HbA1c by 0.4-0.8%

64
Q

GLP1 SE

A

potential weight loss
nausea, vomiting, bloating
hypoglycemia rare

65
Q

Dipeptidyl peptidase-IV inhibitor suffix

A

-sitagliptin

66
Q

Dipeptidyl peptidase-IV inhibitor MOA

A

inhibition of DPP-IV (breaks down GLP1)

67
Q

DDPIV inhibitor effects

A

lowers HbA1C by 0.4-0.8%

68
Q

DDPIV inhibitor Se

A

potential weight loss
nausea vomiting bloating
hypoglycemia rare

69
Q

PKC activation

A

Hyperglycemia causes PKC activation
(increased DAG –> PKC activated)
production of VEGF, TGFB and plasminogen activator inhibitor (procoagulant)

70
Q

Polyol path

A

glucose –> sorbitol –> fructose
NADPH used up, required for glutathione production
oxidative stress
sorbitol –> cataracts